Dose of thalidomide actually administered in patients with MCL
. | . | . | . | Thalidomide dose, mg . | . | |
|---|---|---|---|---|---|---|
| Patient . | Age, y* . | IPI . | Response . | Maximum . | During maintenance . | |
| 1 | 56 | Intermediate-low | PR | 400 | 200 (12 wk) → 100 (26 wk) → 50 (88 wk, continued during retreatment) | |
| 2 | 68 | Intermediate-high | PR | 400 | 400 (8 wk) → 300 (4 wk) → 200 (47 wk) → 100 (19 wk, continued during retreatment) | |
| 3 | 50 | Low | CR | 400 | 400 (70 wk) → 200 (8 wk, continued during retreatment) | |
| 4 | 70 | Intermediate-high | PR | 400 | 400 (8 wk) → 300 (8 wk; discontinued because of neutropenia) | |
| 5 | 74 | Intermediate-high | CR | 400 | 400 (8 wk) → 300 (15 wk) → 200 (32 wk) → 100 (36 wk) | |
| 6 | 65 | Intermediate-high | CRu | 200 | 200 (36 wk) → 100 (42 wk) → 50 (22 wk; discontinued because of neuropathy) | |
| 7 | 64 | Intermediate-high | PR | 200 | 200 (3 wk) → 100 (83 wk) | |
| 8 | 70 | Intermediate-low | SD | 400 | 400 (8 wk) → 200 (15 wk) | |
| 9 | 74 | Intermediate-low | CR | 200 | 200 (20 wk) → 100 (60 wk) → 50 (55+ wk) | |
| 10 | 71 | High | PR | 200 | 200 (36 wk) → 100 (20 wk) | |
| 11 | 62 | Intermediate-high | PR | 200 | 200 (32 wk) → 100 (44+ wk) | |
| 12 | 45 | Low | CR | 200 | 100 (8 wk) → 50 (44+ wk) | |
| 13 | 76 | High | NR | 200 | 100 (8 wk) | |
| 14 | 64 | Intermediate-low | PR | 200 | 200 (20 wk) | |
| 15 | 72 | Intermediate-low | NR | 200 | 200 (8 wk) | |
| 16 | 61 | High | PR | 200 | 200 (12+ wk) | |
. | . | . | . | Thalidomide dose, mg . | . | |
|---|---|---|---|---|---|---|
| Patient . | Age, y* . | IPI . | Response . | Maximum . | During maintenance . | |
| 1 | 56 | Intermediate-low | PR | 400 | 200 (12 wk) → 100 (26 wk) → 50 (88 wk, continued during retreatment) | |
| 2 | 68 | Intermediate-high | PR | 400 | 400 (8 wk) → 300 (4 wk) → 200 (47 wk) → 100 (19 wk, continued during retreatment) | |
| 3 | 50 | Low | CR | 400 | 400 (70 wk) → 200 (8 wk, continued during retreatment) | |
| 4 | 70 | Intermediate-high | PR | 400 | 400 (8 wk) → 300 (8 wk; discontinued because of neutropenia) | |
| 5 | 74 | Intermediate-high | CR | 400 | 400 (8 wk) → 300 (15 wk) → 200 (32 wk) → 100 (36 wk) | |
| 6 | 65 | Intermediate-high | CRu | 200 | 200 (36 wk) → 100 (42 wk) → 50 (22 wk; discontinued because of neuropathy) | |
| 7 | 64 | Intermediate-high | PR | 200 | 200 (3 wk) → 100 (83 wk) | |
| 8 | 70 | Intermediate-low | SD | 400 | 400 (8 wk) → 200 (15 wk) | |
| 9 | 74 | Intermediate-low | CR | 200 | 200 (20 wk) → 100 (60 wk) → 50 (55+ wk) | |
| 10 | 71 | High | PR | 200 | 200 (36 wk) → 100 (20 wk) | |
| 11 | 62 | Intermediate-high | PR | 200 | 200 (32 wk) → 100 (44+ wk) | |
| 12 | 45 | Low | CR | 200 | 100 (8 wk) → 50 (44+ wk) | |
| 13 | 76 | High | NR | 200 | 100 (8 wk) | |
| 14 | 64 | Intermediate-low | PR | 200 | 200 (20 wk) | |
| 15 | 72 | Intermediate-low | NR | 200 | 200 (8 wk) | |
| 16 | 61 | High | PR | 200 | 200 (12+ wk) | |
IPI indicates International Prognostic Index; SD, stable disease; and NR, no response.
Age at the time of initiation of study treatment.